Home » 제품 » Ready-to-Use NGS Panel » Somatic Cancer » CancerMaster
CancerMaster Panel
Comprehensive panel for somatic cancer and immuno-oncology markers
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Hybridization-based target enrichment panel with our intrinsic probe design, rebalancing, and molecular barcode technologies to efficiently analyze not only hard-to-capture areas but also challenging samples, such as damaged DNA or RNA.
View Detail >End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >Revolutionary Bioinformatics solution providing fast and
accurate, client-specific analysis services.
Trust CAS with your BI analysis !
Highly optimized library preparation kit to be used with all Celemics ready-to-use or customized panels. Experience the incomparable efficiency and performance for NGS library preparation
View Detail >The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Celemics’ comprehensive NGS panel for somatic cancer allows highly accurate and comprehensive analysis for identifying significant mutations and variants for solid tumors.
View Detail >The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >Utilizing NGS-based target enrichment methods for higher genotyping efficiency and accuracy. Providing cost-effective and optimized experiment compared to conventional methods, such as GBS, PCR and microarray in plant and animal research
View Detail >Providing NGS-based diagnostics solutions for biopharma companies. Celemics can develop and deliver a flexible customization and commercialization services while maintaining the market-leading performance for our clients interested in clinical and companion diagnostics.
View Detail >Tailored-fit customized assay development from designing to validation run; including not only the custom panel design but also species-specific or sequencer-specific blockers, followed by reagent conditioning to optimize the individual experiment and sequencer.
View Detail >The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Find useful information, insights and tools for your Celemics’ products and services
View Detail >Explore the most up-to-date publications featuring Celemics’ products and services
View Detail >Sharing interesting stories about the world of NGS and how Celemics delivers the innovative NGS solutions to the world of science.
View Detail >Find useful information, insights and tools for your Celemics’ products and services
View Detail >In-silico designed and wet-lab validated exclusive probes to ensure state-of-the-art capture performance
View Detail >Stay up-to-date with the latest updates on our activities, events and achievements
View Detail >Let’s change the NGS market together – our global presence and partners world-wide
View Detail >Waiting for your experience with Celemics, an innovative leader in NGS industry
View Detail >Comprehensive panel for somatic cancer and immuno-oncology markers
CancerMaster 패널은 유전자 내 발생하는 모든 유전 변이에 더하여 면역 치료 반응에 중요한 것으로 알려진 마커 (Immuno-oncology 마커)들을 정밀하게 분석할 수 있는 패널입니다. 특히 CNV 분석에서는 암세포 비율에 따라 다른 Cut-off를 적용한 분석을 진행하며 Epstein-Barr Virus (EBV) 및 Human Papillomaviruses (HPV) 분석 또한 진행 가능해 암 연관 유전자들의 종합적인 분석이 가능합니다.
CancerMaster는 다양한 종류의 암종에 연관된 유전자에 대한 종합적인 분석 결과를 제공하기 위해 개발된 패널입니다. Somatic variants는 물론 TMB, MSI 분석을 위한 Immuno-oncology 마커 및 EBV, HPV와 같은 암 연관 바이러스 분석까지 폭넓은 타겟 범위를 모두 커버할 수 있도록 설계되었습니다
EBV (Epstein-Barr Virus) | HPV (Human Papillomavirus) |
---|---|
- Related disease - Lymphoma - Genes - EBV type1 (EBNA-2) |
- Related disease - Cervical cancer - Genes - HPV L1 gene (Analysis of a total of 24 types is possible) |
Validation for detection of EBV type1 (EBNA - 2) in control specimens |
Analysis of the following 11 types of HPV types was completed using clinical specimens |
![]() |
![]() |
암 연구는 패널 성능은 통한 일관된 결과를 제공할 수 있어야 함은 물론 재현성이 확보되어야 합니다. 셀레믹스의 CancerMaster 패널은 다양한 표준물질 및 일반적인 샘플은 물론 임상 수준의 검체에 대해서도 성능 평가를 완료한 패널입니다.
Variants of CancerMaster (764 Samples)
Gene count* | 524 genes |
---|---|
Covered region | Whole CDS, Custom regions of oncogenes, immune response genes, and EBV & HPV viruses |
Target size | 2.5 Mb |
Mutation type | SNV, Indel, CNV, Rearrangement, TMB, MSI, EBV, HPV |
Sample type | FFPE, Fresh frozen tissue (> 50 ng of fragmented DNA) |
Platform | All sequencers from Illumina, Thermo Fisher, MGI, PacBio, and Oxford Nanopore |
Bioinformatics Support | ① Primary Analysis: FASTQ to annotated VCF ② Secondary Analysis: CNV, Large InDel, MSI, TMB ③ Tertiary Analysis: Clinical interpretation |
ABL1 | ABL2 | ACVR1 | ACVR1B | ADAM29 | ADGRA2 | AKT1 | AKT2 | AKT3 | ALK | ALOX12B | ALOX15B | AMER1 | APC | APCDD1 | APEX1 | APOB | APOBEC1 | APOBEC3 A |
APOBEC3 B |
AR | ARAF | ARFRP1 | ARID1A | ARID1B | ARID2 | ASXL1 | ATM | ATP11B | ATR | ATRX | AURKA | AURKB | AXIN1 | AXL | B2M | B3GAT1 | BACH1 | BAP1 | BARD1 |
BCL2 | BCL2A1 | BCL2L1 | BCL2L2 | BCL6 | BCL9 | BCOR | BCORL1 | BCR | BIRC2 | BIRC3 | BLM | BRAF | BRCA1 | BRCA2 | BRD2 | BRD3 | BRD4 | BRIP1 | BTG1 |
BTK | BTLA | CARD11 | CASP5 | CASP8 | CBFB | CBL | CCDC150 | CCDC168 | CCDC43 | CCL2 | CCL4 | CCND1 | CCND2 | CCND3 | CCNE1 | CD27 | CD274 | CD276 | CD28 |
CD3D | CD3E | CD3G | CD4 | CD40 | CD44 | CD79A | CD79B | CD8A | CDC42 | CDC73 | CDH1 | CDH2 | CDH20 | CDH5 | CDK12 | CDK4 | CDK6 | CDK8 | CDKN1A |
CDKN1B | CDKN2A | CDKN2B | CDKN2C | CDX2 | CEBPA | CHD1 | CHD2 | CHD4 | CHEK1 | CHEK2 | CHUK | CIC | CRBN | CREBBP | CRKL | CRLF2 | CSF1R | CSF2 | CSF2RA |
CSF2RB | CSNK2A1 | CTCF | CTLA4 | CTNNA1 | CTNNB1 | CUL3 | CUL4A | CUL4B | CXCL10 | CXCL11 | CXCL9 | CXCR3 | CYLD | CYP17A1 | DAXX | DCUN1D1 | DDR2 | DICER1 | DIS3 |
DNMT1 | DNMT3A | DOCK2 | DOT1L | EGFR | ELMO1 | EML4 | EMSY | EP300 | EPHA3 | EPHA5 | EPHA6 | EPHA7 | EPHB1 | EPHB4 | EPHB6 | ERBB2 | ERBB3 | ERBB4 | ERCC1 |
ERCC2 | ERG | ERRFI1 | ESR1 | ETV1 | ETV4 | ETV5 | ETV6 | EWSR1 | EYA2 | EZH2 | FAM46C | FANCA | FANCC | FANCD2 | FANCE | FANCF | FANCG | FANCI | FANCL |
FANCM | FAS | FAT1 | FAT3 | FBXW7 | FGF1 | FGF10 | FGF12 | FGF14 | FGF19 | FGF2 | FGF23 | FGF3 | FGF4 | FGF6 | FGF7 | FGFR1 | FGFR2 | FGFR3 | FGFR4 |
FH | FLCN | FLT1 | FLT3 | FLT4 | FOXA1 | FOXL2 | FOXO3 | FOXP1 | FOXP3 | FRS2 | FUBP1 | GABRA6 | GAS6 | GATA1 | GATA2 | GATA3 | GATA4 | GATA6 | GID4 |
GLI1 | GNA11 | GNA13 | GNAQ | GNAS | GRIN2A | GRM3 | GSK3B | GUCY1A2 | GZMA | GZMB | GZMH | H3F3A | HGF | HIST1H3B | HLA-A | HLA-B | HLA-C | HLA-DRA | HLA-E |
HLA-F | HLA-G | HNF1A | HOXA3 | HRAS | HSD3B1 | HSP90AA1 | IDH1 | IDH2 | IDO1 | IDO2 | IFITM1 | IFITM3 | IFNA1 | IFNB1 | IFNG | IGF1 | IGF1R | IGF2 | IGF2R |
IKBKE | IKZF1 | IL12A | IL12B | IL2 | IL23A | IL6 | IL7R | INHBA | INPP4B | INSR | IRF2 | IRF4 | IRS2 | ITGAE | ITK | JAK1 | JAK2 | JAK3 | JUN |
KAT6A | KDM5A | KDM5C | KDM6A | KDR | KEAP1 | KEL | KIT | KLF4 | KLHL6 | KMT2A | KMT2B | KMT2C | KNSTRN | KRAS | LAG3 | LMO1 | LRP1B | LRP6 | LTK |
LYN | LZTR1 | MAGI2 | MAGOH | MAML1 | MAP2K1 | MAP2K2 | MAP2K4 | MAP3K1 | MAP3K13 | MAPK1 | MAX | MCL1 | MDM2 | MDM4 | MED12 | MEF2B | MEN1 | MET | MITF |
MLH1 | MPL | MRE11 | MSH2 | MSH6 | MTOR | MUTYH | MYB | MYC | MYCL | MYCN | MYD88 | MYO18A | NCOA3 | NCOR1 | NF1 | NF2 | NFE2L2 | NFKBIA | NKX2-1 |
NKX2-8 | NKX3-1 | NOTCH1 | NOTCH2 | NOTCH3 | NOTCH4 | NPM1 | NRAS | NSD1 | NSD3 | NTRK1 | NTRK2 | NTRK3 | NUP93 | NUTM1 | PAK3 | PAK5 | PALB2 | PARK2 | PARP1 |
PARP2 | PARP3 | PARP4 | PAX5 | PBRM1 | PDCD1 | PDCD1LG2 | PDGFRA | PDGFRB | PDK1 | PGR | PHF6 | PHLPP2 | PIK3C2B | PIK3C3 | PIK3CA | PIK3CB | PIK3CG | PIK3R1 | PIK3R2 |
PKHD1 | PLCG1 | PLCG2 | PMS2 | PNP | PNRC1 | POLD1 | POLE | PPARG | PPP2R1A | PRDM1 | PREX2 | PRF1 | PRKAR1A | PRKCI | PRKDC | PRPF40B | PRSS8 | PTCH1 | PTCH2 |
PTEN | PTK2 | PTPN11 | PTPRC | PTPRD | QKI | RAB35 | RAC1 | RAC2 | RAD17 | RAD50 | RAD51 | RAD51B | RAD51C | RAD51D | RAD52 | RAD54L | RAF1 | RANBP2 | RARA |
RB1 | RBM10 | REL | RET | RHEB | RHOA | RHOB | RICTOR | RNF43 | ROBO1 | ROBO2 | ROS1 | RPA1 | RPS6KB1 | RPTOR | RUNX1 | RUNX1T1 | RUNX3 | SDHA | SDHB |
SDHC | SDHD | SEMA3A | SEMA3E | SET | SETBP1 | SETD2 | SF3A1 | SF3B1 | SH2B3 | SKP2 | SLIT2 | SMAD2 | SMAD3 | SMAD4 | SMARCA1 | SMARCA4 | SMARCB1 | SMARCD1 | SMO |
SNCAIP | SOCS1 | SOX10 | SOX2 | SOX9 | SPEN | SPOP | SPTA1 | SRC | SRSF1 | SRSF2 | SRSF7 | STAG2 | STAT3 | STAT4 | STK11 | SUFU | SYK | TACC3 | TAF1 |
TBX22 | TBX3 | TERC | TERT | TET2 | TGFBR2 | TIAF1 | TIGIT | TIPARP | TMPRSS2 | TNF | TNFAIP3 | TNFRSF14 | TNFRSF18 | TNFRSF4 | TNFSF13B | TNKS | TNKS2 | TOP1 | TOP2A |
TP53 | TRAF7 | TRRAP | TSC1 | TSC2 | TSHR | U2AF1 | U2AF2 | USP9X | VEGFA | VHL | VSIR | VTCN1 | WISP3 | WNT1 | WT1 | WWP1 | XBP1 | XPO1 | XRCC3 |
ZBTB2 | ZNF217 | ZNF703 | ZRSR2 |
암종과 연관 있는 것으로 알려진 유전자의 염기서열을 포괄적으로 분석하기 위한 패널. Immuno-oncology 마커를 비롯해 Gene Rearrangement 등 다양한 유전 변이를 분석하기 위한 패널
FDA 승인된 약물과 연관있는 것으로 알려진 유전변이 검출을 위한 패널로 약물과 연관성이 높은 주요 유전자를 폭넓게 커버하는 패널
암종과 연관 있는 것으로 알려진 유전자의 염기서열을 포괄적으로 분석하기 위한 패널. Immuno-oncology 마커를 비롯해 Gene Rearrangement 등 다양한 유전 변이를 분석하기 위한 패널
유전성 암과 연관 있는 것으로 보고된 30여 개 유전자의 염기서열 분석을 위한 패널
FDA 승인된 약물과 연관있는 것으로 알려진 유전변이 검출을 위한 패널로 약물과 연관성이 높은 주요 유전자를 폭넓게 커버하는 패널
셀레믹스에서 제공하는 BI 분석 서비스로 다양한 수준의 분석 결과 제공 가능
Technical Resources
[Product Overview] CancerMaster Panel
[Product Overview] Celemics Target Enrichment Panel Overview
[Catalogue] Celemics Products & Service Catalogue_All Products & Service
Safety Data Sheets
MSDS_CancerMaster Panel_Illumina_Enzymeplus
MSDS_CancerMaster Panel_Illumina
MSDS_CancerMaster Panel_Thermo Fisher
MSDS_CancerMaster Panel_MGI_EnzymePlus
MSDS_CancerMaster Panel_MGI
Bae JM, Ahn JY, Lee H, Jang H, Han H, Jeong J, et al. Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel. Epigenomics. 2022 May;14(10):615–28.
10.2217/epi-2021-0477
So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022 May;63(3):294–300.
DOI 10.4111/icu.20220044
Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci Rep. 2022 Feb 3;12(1):1842.
DOI 10.1038/s41598-022-05931-3
Shin WY, Yoon SY, Park R, Kim JA, Song HH, Bang HI, et al. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report. BMC Med Genomics. 2022 Mar 4;15(1):46.
DOI 10.1186/s12920-022-01191-2